Showing articles with keyword: Notre Dame | CLEAR
May 16, 2018
CTSI to Fund Notre Dame Early Childhood Needs Research
By Erin Blasko:
The University of Notre Dame is partnering with Ready to Grow St. Joe to assess the social, emotional, physical and cognitive development of children age birth to eight in St. Joseph County — part of an effort to better inform future health prevention and intervention efforts in the county, where 30 percent of young children live in poverty.
Financed with a $25,000 Community Health Partnerships grant from the Indiana CTSI, the assessment will document the current status of young children in the county and the need for programming and policy to address gaps and promote improved health and well-being.
May 14, 2018
Training Opportunity: New Tool for Understanding ‘Omics Data
The Indiana CTSI has made available a shared license for QIAGEN’s Ingenuity Pathway Analysis (IPA), a powerful analysis and search tool that uncovers the significance of ‘omics data and identifies new targets or candidate biomarkers within the context of biological systems. With its many features, IPA allows you to quickly understand and visualize your data.
IU, Purdue and Notre Dame researchers can purchase sub-licenses to use this product. The new licensing period is from July 1, 2018, to June 30, 2019.
If you’re interested in learning more, please join us at one of the free IPA training workshops listed below. These hands-on sessions...
March 27, 2018
Notre Dame Researcher Receives CTSI Postdoctoral Award
By Brandi Klingerman:
Postdoctoral Scholar Henry Clay Conner
Henry Clay Conner, University of Notre Dame postdoctoral scholar, has received a Postdoctoral Training Award in Translational Research from the Indiana Clinical and Translational Sciences Institute (CTSI). The award will be used for his work in Athanasia Panopoulos’s lab.
Dr. Panopoulos, the Elizabeth and Michael Gallagher Assistant Professor of Biological Sciences, director of the Flow Cytometry Core Facility, and affiliated member of the Harper Cancer Research Institute, and her team are focused on using induced pluripotent stem (iPS) cells, or cells that have been reprogrammed to behave as though they are in an embryonic-like state. The iPS cells are utilized as a system...
January 18, 2017
Applications Sought for Design and Biostatistics Program Pilot Grant
Design and Biostatistics Program (DBP) Pilot Grant – 2017.02
LETTER OF INTENT (LOI) DEADLINE – DECEMBER 16, 2016
FULL APPLICATION DEADLINE – FEBRUARY 6, 2017 (5:00 PM)
The Design and Biostatistics Program (DBP) of the Indiana Clinical and Translational Science Institute (CTSI) is comprised of 8 units with associated expertise: 1) Department of Biostatistics, IU School of Medicine and Fairbanks School of Public Health; 2) Division of Hereditary Genomics, Department of Medical & Molecular Genetics, IU School of Medicine; 3) Computational Biology, Center for Computational Biology & Bioinformatics, IU School of Medicine; 4) Department of Epidemiology, Fairbanks School of Public Health; 5)...
January 10, 2017
Applications Sought for IIMR VA Young Investigator Award
LETTER OF INTENT (LOI) DEADLINE- JANUARY 18, 2017
APPLICATION SUBMISSION DEADLINE – FEBRUARY 08, 2017
IIMR’s mission is to promote and enhance research efforts that will ultimately result in improved quality of life for veterans and for the greater population. In support of that mission, IIMR works to encourage investigators to develop their research careers by working with IIMR and the VA and veterans to answer important questions. One way IIMR encourages investigators is to sponsor the annual Young Investigator Award Program, which provides a competitive experience for investigators to explore the possibilities of VA-related research.
The IIMR is currently seeking submissions...
November 1, 2016
Carmel Egan Joins Indiana CTSI
Carmel Egan, PhD
Carmel Egan, PhD, a top project management and product development executive at Eli Lilly and Co., has joined the Indiana University School of Medicine as project leader of IU’s Precision Health Initiative.
Dr. Egan, vice president, Medicines Development Unit at Lilly, has held a series of leadership positions at Lilly. Prior to her most recent position at Lilly, she served as Vice President of special Alzheimer’s disease initiatives in Lilly’s Biomedicines Business Unit and previously as Vice President of LRL Portfolio and Project Management.
She will coordinate activities of the Precision Health Initiative as part of her role as...